Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02.
about
Current trends in the surgical management and treatment of adult glioblastomaMolecular characterizations of glioblastoma, targeted therapy, and clinical results to dateEmerging targeted therapies for glioma.A randomized trial of bevacizumab for newly diagnosed glioblastomaAdvanced magnetic resonance imaging of the physical processes in human glioblastoma.Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma.Phase I study of the combination of temsirolimus and pazopanib in advanced solid tumorsRecurrent malignant gliomas.Antiangiogenic therapy for glioblastoma: current status and future prospects.Glial progenitors as targets for transformation in glioma.Deregulated proliferation and differentiation in brain tumors.The mTOR signaling pathway as a treatment target for intracranial neoplasmsGrowth-factor-driven rescue to receptor tyrosine kinase (RTK) inhibitors through Akt and Erk phosphorylation in pediatric low grade astrocytoma and ependymomaLessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma.PI3K pathway inhibitors: potential prospects as adjuncts to vaccine immunotherapy for glioblastoma.Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic ReviewMolecular interactions of ErbB1 (EGFR) and integrin-β1 in astrocytoma frozen sections predict clinical outcome and correlate with Akt-mediated in vitro radioresistance.The Methanol Extract of Angelica sinensis Induces Cell Apoptosis and Suppresses Tumor Growth in Human Malignant Brain TumorsStandards of care and novel approaches in the management of glioblastoma multiforme.Bevacizumab for the treatment of glioblastoma.Antiangiogenic therapy for high-grade gliomas: current concepts and limitations.Targeted therapy in gliomas.Prognostic and predictive biomarkers in adult and pediatric gliomas: toward personalized treatment.Toward precision medicine in glioblastoma: the promise and the challenges.Glioblastoma targeted therapy: updated approaches from recent biological insights.Disease progression in recurrent glioblastoma patients treated with the VEGFR inhibitor axitinib is associated with increased regulatory T cell numbers and T cell exhaustion.Population pharmacokinetics of temsirolimus and sirolimus in children with recurrent solid tumours: a report from the Children's Oncology Group.Inhibition of Autophagy by Chloroquine Enhances the Antitumor Efficacy of Sorafenib in Glioblastoma.Investigational new drugs for brain cancer.Targeting the VEGF and PDGF signaling pathway in glioblastoma treatment.Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future.Sorafenib inhibits cell growth but fails to enhance radio- and chemosensitivity of glioblastoma cell lines.EGFR and PDGFRA co-expression and heterodimerization in glioblastoma tumor sphere lines.Human mesenchymal stromal cells as cellular drug-delivery vectors for glioblastoma therapy: a good deal?Temsirolimus controlled metastatic advanced renal cell carcinoma for over 4 years: a case study.Cytoplasmic p53 couples oncogene-driven glucose metabolism to apoptosis and is a therapeutic target in glioblastoma.Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572.Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02.The diagnostic role and clinical relevance of determination of BRAF status in brain tumors.
P2860
Q26799854-64AD3A22-4C11-4780-B40E-7922F5B9456CQ26822717-E35BFDD8-27DD-479F-B03D-23D983145DE0Q30241853-7402F8CD-A27F-4676-A5DB-BC3F5B2D238CQ30410163-1F84E6FB-9DB2-42F4-8BBA-F17042D06294Q30847284-CBBE1052-6E68-42DE-91D6-A2F500CAD5DAQ33414998-C4917AB0-F815-4CD4-83FC-0E76CCF757B0Q34129269-86B68437-CD2E-4013-935E-146BF32E7A10Q34438507-7A9E6CDB-7C24-4BE6-8AA5-052CEA078C8EQ34523319-EBAA272B-CAB3-46D5-831C-B5200D78D6CEQ34735661-608DE396-CFC5-4EA8-B44C-79BCB4505B61Q34859989-BF13121E-D5FA-4AF4-B8E4-FEDE1B00EE56Q34886859-3B552264-B703-4C27-B7EC-5680EAF6E668Q35583984-EBA18D38-23A6-4F25-A206-7C3246839C32Q35895174-E9404D5A-65BA-4A8A-BA70-9741AD5049CBQ36086507-6CA5CA5E-456A-4927-B465-C97AB3231414Q36270115-6817C013-9268-4D60-8085-37BD638F6A58Q37021563-9BBB3A30-C267-4DF8-B58C-D8F39C2FD019Q37351460-A39DE3E1-6E41-44D8-8A47-FE5232657F7DQ37525881-AA75E43C-E66F-4ED1-BAE9-5DC164FE755FQ38129428-EFF1E6C4-70A8-489A-BF59-A8A59547FA33Q38157034-D6213605-1BCA-498B-A738-BEDA090D67F0Q38186656-5CC8A67B-BBF8-482E-BE59-D331C714ED78Q38203283-1E693984-8AE0-4C0B-8D39-7388BC2B5507Q38454659-55DED7DB-B372-4830-839B-9B7BE6D161B2Q38597700-2FF24DA1-DE6B-45CB-A28F-2170E0D74B9CQ38776701-D3D6A2E5-C312-4908-91F9-FBE75933B268Q38779903-EAC2AD66-3A63-41E2-A539-AEC82535F39DQ38786782-1CD8AA76-1663-43F8-A5E2-7D422487D44EQ38832510-DB442021-5A52-43D3-A7F8-4A8CD4709421Q38838030-FC30C4AA-B927-4391-9E63-FFEB8139016BQ38849515-8043F77B-638F-4CC2-A132-641A00231EA8Q39472878-12373551-0113-4186-A29A-ADD149226841Q41490623-8107C0A2-4539-4BDD-8898-F435378205F3Q42368133-CF930A72-2B82-4859-A4B7-0A3482BD85FBQ44688559-799AB398-EB43-4D56-9A0A-0334E72584B2Q46311981-690D90DB-CC50-494E-93AC-40729F0B39B3Q47219387-3ED4F89E-ACDC-4CCF-BEEC-68B9C6B76502Q49501093-9BBB3153-CB4D-44BB-8D05-305DF374C986Q55461604-A0E15384-1D99-4B9D-B0DE-2CC428D106DC
P2860
Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02.
description
2012 nî lūn-bûn
@nan
2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Phase I/II study of sorafenib ...... Tumor Consortium study 05-02.
@ast
Phase I/II study of sorafenib ...... Tumor Consortium study 05-02.
@en
type
label
Phase I/II study of sorafenib ...... Tumor Consortium study 05-02.
@ast
Phase I/II study of sorafenib ...... Tumor Consortium study 05-02.
@en
prefLabel
Phase I/II study of sorafenib ...... Tumor Consortium study 05-02.
@ast
Phase I/II study of sorafenib ...... Tumor Consortium study 05-02.
@en
P2093
P2860
P356
P1433
P1476
Phase I/II study of sorafenib ...... Tumor Consortium study 05-02.
@en
P2093
Eudocia Q Lee
Frank Lieberman
H Ian Robins
Jan Drappatz
Janet E Dancey
John J Wright
Kathleen R Lamborn
Kenneth Aldape
Lauren Abrey
P2860
P304
P356
10.1093/NEUONC/NOS264
P577
2012-10-24T00:00:00Z